Background: Cerebral venous thrombosis (CVT) is a rare but potentially debilitating form of stroke. Current management guidelines recommend a course of low molecular weight heparin (LMWH) followed by an oral vitamin K antagonist. However, there is an emerging body of evidence to support the use of direct oral anticoagulant (DOAC) medications. Here, we assess the efficacy of rivaroxaban compared to the standard of care in a resource‐limited setting. Methods: The study was designed as a Phase III, prospective, parallel, open‐label, randomized controlled trial conducted in three sites in Syria. Seventy‐one participants met inclusion criteria and were randomized 1:1 to receive either rivaroxaban or warfarin following initial bridging with LMWH for 3.5–12 days. The primary outcome was functional improvement determined by the Barthel Index. Secondary outcomes were adverse events during follow‐up, including CVT recurrence, thrombotic events, intracranial pressure (ICP) requiring shunt placement, extra and intracranial bleeding, neurological deficit, and all‐cause mortality. Results: Barthel Index scores did not differ between the study cohorts at 1‐, 2‐, 3‐, 4‐, 5‐, or 6‐month follow‐up. Secondary analysis yielded no difference in rates of adverse effects or return of CVT. Two patients in the warfarin group developed major extracranial bleeds (uterine bleeding); however, there were no other extracranial or intracranial bleeds or thrombotic events reported. Rates of all‐cause mortality and all assessed adverse effects were similar between the groups. Conclusion: We offer a prospective, parallel randomized controlled trial that suggests rivaroxaban may have comparable safety and efficacy when compared to warfarin for the treatment of CVT. Importantly, we offer the first randomized control trial of oral anticoagulants for the treatment of CVT in a resource‐limited setting, providing support for the evolving literature and suggesting the safety and efficacy of oral anticoagulants in the management of CVT. Trial Registration: ClinicalTrials.gov identifier: NCT04569279
Background and Purpose: Small fiber neuropathy (SFN), resulting from dysfunction and loss of peripheral unmyelinated and thinly myelinated nerve fibers, is traditionally characterized by distal skin pain and sensory loss. Patients often report additional symptoms, including muscle cramps, myalgias, fatigue, subjective weakness, and neuropathic itch, but the prevalence and intensity of these symptoms remain poorly defined. Current treatments—focused primarily on pain—are often ineffective, possibly due to substantial between‐patient heterogeneity. This study aimed to characterize the symptomatic variability of SFN and determine whether patients can be stratified into clinically meaningful subgroups.Methods: Demographic, clinical, and laboratory data were analyzed from patients with skin biopsy‐confirmed SFN (n = 203) and healthy controls (n = 30). SFN patients were clustered based on clinical features using unsupervised machine learning.Results: Fatigue—not neuropathic pain—was the most prevalent and intense symptom among patients with SFN. Muscle symptoms were as common and severe as neuropathic pain, while neuropathic itch was rare. Three distinct phenotypic clusters were identified: (1) an “algesic” group (~20%) with severe neuropathic pain and co‐occurring intense symptoms; (2) a “myalgic” group (~60%) with prominent fatigue, myalgias, and subjective weakness but milder neuropathic pain; and (3) a “pauci‐symptomatic” group with few, mild to moderate symptoms. Clusters differed by symptom profiles, disease duration, intraepidermal nerve fiber density, sex, and body mass index.Conclusion: Fatigue and muscle symptoms are highly prevalent in SFN and may rival pain in clinical importance. Identifying patient subgroups provides a foundation for stratified treatment approaches and improved disease management.
Background: Sacral nerve stimulators (SNSs) can be an effective treatment for urinary incontinence. However, with a failure rate of up to 50%, an explantation rate of up to 16%, and a cost of ~USD 10,000 per implant, identification of patients at high risk for explantation is necessary to improve patient satisfaction and reduce the economic burden on the healthcare system. The objective of this retrospective cohort study was to determine predictors of SNS explantation within the first two years of device placement. Methods: The MOVER database was queried for patients with a SNS and at least two years of follow-up (n = 54). Multivariate logistic regression was performed to assess risk factors for explantation. Factor optimization was used to eliminate factors with limited predictive value. Results: The model displayed excellent performance with an AUC of 0.93 (95% CI: 0.78–1.00) and an f1-score of 0.81. Female sex (OR: 3.75; CI: 3.71–3.79), malignancy (OR: 3.14; CI: 3.10–3.18), ASA score (OR: 2.53; CI: 2.50–2.57), peripheral neuropathy (OR: 2.04: CI: 2.01–2.07), alcohol use (OR: 1.98; CI: 1.96–2.01), and length of stay (OR: 1.47; CI: 1.45–1.49) displayed statistically significant increased risk of explantation. Atrial fibrillation (OR: 0.36; CI: 0.35–0.36) and chronic kidney disease (OR: 0.54; CI: 0.53–0.54) were included in the model but conferred decreased risk of explantation. Conclusions: Patient ASA score and a medical history of malignancy, peripheral neuropathy, and alcohol use are possible novel risk factors for SNS explantation.
Background: Experimental models using Plasmodium berghei ANKA (PbA)-infected mice have been essential for uncovering cerebral malaria (CM) pathogenesis. However, variability in experimental CM (ECM) incidence, onset, and mortality introduce challenges when analyses rely solely on infection day, which may reflect different disease stages among animals. Methods: We applied machine learning to predict ECM risk and onset in a cohort of 153 C57BL/6, 164 CBA, and 53 Swiss Webster mice. First, we fitted a logistic regression model to estimate the risk of ECM at any day using parasitemia data from day 1 to day 4. Next, we developed and trained a Random Forest Regressor model to predict the exact day of symptom onset. Results: A total of 64.5% of the cohort developed ECM, with onset ranging between 5 and 11 days. Early increases in parasitemia were strong predictors for the development of ECM, with an increase in parasitemia equal to or greater than 0.05 between day 1 and day 3 predicting the development of ECM with 97% sensitivity. The Random Forest model predicted the day of ECM onset with high precision (mean absolute error: 0.43, R2: 0.64). Conclusion: Parasitemia dynamics can effectively identify mice at high risk of ECM, enabling more accurate modeling of early pathological processes and improving the consistency of experimental analyses.
Background: Sacral nerve stimulators (SNS) can be an effective treatment for urinary incontinence. However, with a failure rate of up to 50%, an explantation rate of up to 16%, and a cost of ~US$10,000 per implant, identification of patients at high risk for explantation is necessary to improve patient satisfaction and reduce the economic burden on the healthcare system. The objective of this retrospective cohort study was to determine predictors of SNS explantation within the first two years of device placement. Methods: The MOVER database was queried for patients with a SNS and at least two years of follow up (n = 54). Multivariate logistic regression was performed to assess risk factors for explantation. Factor optimization was used to eliminate factors with limited predictive value. Results: The model displayed excellent performance with an AUC of 0.93 and an f1-score of 0.81. Malignancy (OR: 3.88; CI: 3.84 – 3.93), female sex (OR: 3.72; CI: 3.68 – 3.76), ASA score (OR: 2.39; CI: 2.36 – 2.42), alcohol use (OR: 2.08; CI: 2.06 – 2.08), length of stay (OR: 1.92; CI: 1.90 – 1.94), peripheral neuropathy (OR: 1.86: CI: 1.83 – 1.88), and low back pain (OR: 1.82; CI: 1.79 – 1.84) displayed statistically significant increased risk of explantation. Atrial fibrillation (OR: 0.38; CI: 0.37 – 0.38) and chronic kidney disease (OR: 0.47; CI: 0.47 – 0.48) were included in the model but conferred decreased risk of explantation. Conclusions: Patient’s ASA score, medical history of malignancy, alcohol use, low back pain, and peripheral neuropathy are possible novel risk factors for SNS explantation.
Background: Spinal cord stimulators can offer an effective treatment in chronic pain refractory to conventional medical management. However, with a failure rate of up to 44% and an annual explantation rate of 6–9%, there is a need to better identify patients at high risk for therapeutic failure. The objective of this retrospective cohort study was to determine predictors of early SCS explantation following device placement. Methods: The Medical Informatics Operating room Vitals and Events Repository database was queried for patients with a spinal cord stimulator and at least two years of follow-up (n = 56). A multivariate logistic regression was fitted. Recursive factor elimination with cross-validation and L1 penalization were used to reduce the number of predictors and minimize the risk of overfitting. The model was used to predict risk factors for explantation, odds ratio (OR), 95% confidence interval (CI), and false discovery rate-adjusted p-value. Results: The final model displayed adequate performance with an average precision of 0.769. Sleep disorders were identified as a statistically significant predictor of SCS explantation (OR: 3.88, CI: 1.36–11.04, FDR p-value: 0.0497). Conclusions: While further prospective studies are needed, our study indicates that sleep disorders are a risk factor for spinal cord stimulator explantation and should be considered during pre-operative evaluation.